Arthneeti
TM

Themis Medicare Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Themis Medicare Ltd Q1 FY26 Results & Presentation Highlights: Revenue ₹97.58 Cr, PAT ₹14.22 Cr

Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹118
Market cap₹1.1K Cr
Updated24 Sept 2026
Read4 min read

Based on Themis Medicare Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8). Q1 FY26 EBITDA: -₹10.08 Cr (negative 10.33% margin), down from ₹29.18 Cr (23.72% margin) in Q1 FY25, representing a 135% YoY decrease.

From Themis Medicare Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8).
  • Formulation Segment grew 35% quarter-on-quarter in Q1 FY26 (Page 8).
  • Revenue from Hospital business expanded 49% quarter-on-quarter in Q1 FY26 (Page 8).
  • Revenue from Trade business expanded 165% quarter-on-quarter in Q1 FY26 (Page 8).
  • API business showed 52% quarter-on-quarter growth in Q1 FY26 (Page 8).
  • Management expects a better bounce back in subsequent quarters with all strategic efforts gaining pace (Page 5).
  • API business showed 77% year-on-year growth in Q1 FY26, indicating early signs of stability and better visibility for the rest of the year (Page 5).

2 more points management made on revenue & sales performance

Profitability & Margins

See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The presentation does not explicitly detail any specific capex amounts, capacity expansions, or new plant/projects with associated timelines or current status. However, related information includes: - Manufacturing Facilities: - Three state-of-art manufacturing sites located at Haridwar (Formulations), Hyderabad (Synthetic APIs), and Vapi (Synthetic APIs). - Capacities per annum: - Tablets: 520 million - Ointment tubes: 9 million - Ampoules: 36 million - Vials: 12 million - Pre-filled syringes: 6 million - Synthetic API capacities: 120 MT (Hyderabad) and 191 MT (Vapi) - R&D Investment: - Continued investments in R&D with yearly expenditure around Rs. 13-14 Cr (FY21 to FY25).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report or mention any details about order book, order inflow, or pending orders. It primarily focuses on: - Financial results and business segments performance - R&D investments and capabilities - Hospital business opportunities and growth strategies

2 more points management made on order book & pipeline

Themis Medicare Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Themis Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • NGL Fine Chem Ltd (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY26 investor presentation — and how it ranks a

  • Influx Healthtech Ltd (Q1 FY26)

    FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key investor presentation takeaways from Influx Healthtech Ltd'

  • Shree Ganesh Remedies Ltd (Q1 FY26)

    Q1FY26 Revenue from Operations: ₹24.67 crores . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY26 investor presentation — and how it

  • Anuh Pharma Ltd (Q1 FY26)

    Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. Key investor presentation takeaways from Anuh Pharma

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Themis Medicare Ltd Q1 FY26 results?

Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8). Q1 FY26 EBITDA: -₹10.08 Cr (negative 10.33% margin), down from ₹29.18 Cr (23.72% margin) in Q1 FY25, representing a 135% YoY decrease.

What is Themis Medicare Ltd share price analysis?

Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.

Is Themis Medicare Ltd planning capital expenditure?

The presentation does not explicitly detail any specific capex amounts, capacity expansions, or new plant/projects with associated timelines or current status.

Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.